Background: The objective of this paper is to analyze the role of bone marrow-derived mesenchymal stem cells (BM-MSCs) on the differentiation of T follicular helper (Tfh) cells in lupus-prone mice. Methods: Bone marrow cells were isolated from C57BL/6 (B6) mice and cultured in vitro, and surface markers were identified by flow cytometry. Naı¨ve CD4 þ T cells, splenocytes and Tfh cells were isolated from B6 mice spleens and co-cultured with BM-MSCs. The proliferation and the differentiation of CD4 þ T cells and Tfh cells were analyzed by flow cytometry. Lupus-prone MRL/Mp-lpr/lpr (MRL/lpr) mice were treated via intravenous injection with expanded BM-MSCs, the differentiation of Tfh cells was detected, and the relief of lupus nephritis was analyzed. Results: MSCs could be successfully induced from bone marrow cells, and cultured BM-MSCs could inhibit T cell proliferation dose-dependently. BM-MSCs could prevent Tfh cell development from naı¨ve CD4 þ T cells and splenocytes. BM-MSCs could inhibit IL-21 gene expression and cytokine production and inhibit isolated Tfh cells and STAT3 phosphorylation. In vivo study proved that BM-MSCs intravenous injection could effectively inhibit Tfh cell expansion and IL-21 production, alleviate lupus nephritis, and prolong the survival rate of lupus-prone mice. Conclusions: BM-MSCs could effectively inhibit the differentiation of Tfh cells both in vitro and in vivo. BM-MSC treatment could relieve lupus nephritis, which indicates that BM-MSCs might be a promising therapeutic method for the treatment of SLE. Lupus (2018) 27, 49-59.
Background
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that involves multiple organ systems. 1 Immune disorders play a key role in the pathogenesis of SLE; [1] [2] [3] over-production of autoantibodies is a consistent feature and is therefore likely to be fundamental to the disease. 1 The production of autoantibodies relies on T-cell-assisted B cell activation, and thus, regulation of up-stream T cells might be a feasible treatment approach to limit overactivation of B cells in SLE. 1, 4, 5 Mesenchymal stem cells (MSCs) are pluripotent stem cells with the ability to differentiate into different cell lineages. 6 MSCs are originally isolated from the bone marrow stroma; bone marrowMSCs (BM-MSCs) could be classically expanded in vitro by consecutive passages in fibroblast growth factor-supplemented cell culture medium. 6, 7 Recently, MSCs have also been identified in other tissues, such as fat, epidermis, and cord blood. 7, 8 MSCs exhibit immunoregulatory activities on multiple immune cells like T lymphocytes, B lymphocytes, dendritic cells, natural killer (NK) cells, and other immune cells. [9] [10] [11] MSCs can induce a shift in T cells from a pro-inflammatory state to an anti-inflammatory state, and can also elicit the differentiation of regulatory T cells, which further inhibits lymphocyte proliferation and inflammatory cytokine production. 12, 13 In addition, MSCs inhibit B-cell proliferation and antibodies production, and this inhibitory effect might be mediated by T cells. 7, 14, 15 Because of the low immunogenicity and remarkable expansion potential, MSCs have a wide range of potential clinical applications, and are considered to be an ideal cell therapy for the treatment of autoimmune diseases, including SLE, rheumatic arthritis (RA), and systemic sclerosis (SSc). 6, 7, [16] [17] [18] The available data from clinical studies have suggested that BM-MSCs are used to treat autoimmune diseases like SLE, but the definite therapeutic mechanisms are not clearly elucidated. 7, 17 Thus, it is important to further investigate the molecular immune mechanisms of BM-MSCs since these can help in the better application of these cells.
T follicular helper (Tfh) cells, a CD4 þ T-cell subset found in germinal centers (GC), express high levels of C-X-C chemokine receptor type 5 (CXCR5), programmed death-1 (PD-1), and inducible costimulatory molecule (ICOS), and the transcription factors are B-cell leukemia/lymphoma 6 (Bcl-6) and Signal Transducer and Activator of Transcription 3 (STAT3). 19, 20 Tfh cells mainly produce interleukin (IL)-21, which helps B cell activation, differentiation, expansion, and antibody production, as well as the formation of GC. 19, [21] [22] [23] Recently, numerous reports proved that Tfh cells play key roles in the pathogenesis of autoimmune diseases like SLE, RA, and SSc. 24 Expanded circulating Tfh cells could be detected in SLE patients, 24, 25 and increased numbers of CD4 þ
CXCR5
þ PD-1 þ Tfh cells could also be found in different strains of lupus-prone mice. [26] [27] [28] Our previous study demonstrated expanded circulating CD4 þ
þ PD-1 þ Tfh cells in active SLE patients is closely related to autoantibody production and disease activity. 26 In addition, we also found that CD4 þ
þ PD-1 þ Tfh cells were expanded in lupus-prone MRL/lpr mice, and related to GC formation and antibody production. 27 All together, these data indicate that Tfh cells are closely related to the hyper-function of humoral immunity in lupus, and Tfh cells play key roles in the occurrence and development of lupus. Thus, Tfh cells could be a promising therapeutic target for SLE treatment.
Here, isolated bone marrow cells from B6 mice were cultured and induced into MSCs, and surface markers were identified by flow cytometry. In vitro study proved that BM-MSCs could prevent Tfh cell development from naı¨ve CD4 þ T cells and sorted Tfh cells. MSCs could also inhibit IL-21 gene expression and cytokine production, and STAT3 phosphorylation in isolated Tfh cells. In vivo study proved that BM-MSCs intravenous injection could effectively inhibit Tfh cell expansion and IL-21 production, decrease urine protein, alleviate lupus nephritis, and prolong the survival rate of lupus mice. All together, these data determined that BM-MSCs could effectively inhibit the differentiation of Tfh cells both in vitro and in vivo, and BM-MSCs might be a promising therapeutic method for the treatment of SLE.
Materials and methods

Mice
Female MRL/lpr mice (8-12 weeks of age) and ageand sex-matched C57BL/6 (B6) mice were purchased from the Shanghai Laboratory Animal Center (Chinese Academy of Sciences). All mice were maintained under pathogen-free conditions. The animal study was approved by Animal Ethics Committees of Huashan Hospital, Fudan University.
MSCs culture and amplification
Bone marrow cells were isolated through density gradient centrifugation for six weeks from B6 mice, and cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 (1:1) supplemented with 1% penicillin, 1% streptomycin, 1% Glutamin-Max, and 15% fetal bovine serum (FBS). After 48 hours in culture, non-adherent cells were removed, and spindle fibroblast-like MSCs were selected by their adherence to the culture dishes. MSCs were expanded to passage fourth and then digested for later experiments. Cultured MSCs were then tested for surface marker expression via flow cytometry.
T cell culture and differentiation
For Tfh cell differentiation, naı¨ve CD4 þ T cells were purified by immune magnetic bead (Miltenyi Biotec), and stimulated with 10 ng/ml IL-21 (Sigma-Aldrich, St. Louis, MO, USA), 20 ng/ml IL-6 (Sigma-Aldrich), 2 mg/ml anti-CD3 antibody (eBiosience, San Diego, CA, USA), and 2 mg/ml anti-CD28 (eBiosience) antibody for five days. 
Treatment and histopathology
The onset of autoimmune diseases in MRL/lpr mice was monitored by the assessment of proteinuria. After clinical onset of disease, MRL/lpr mice were treated via tail vein injection with 2 Â 10 6 BMMSCs or saline vehicle twice (at week 18 and week 20) , then sacrificed at eight weeks after the last treatment. For detection of urine protein, the total urine from 24 hours was first collected, and performed via coomassie blue staining according to the manufacturer's directions (Najing Jiancheng, China). At the time of sacrifice, the tissues were fixed with formaldehyde, embedded in paraffin, and stained with hematoxylin and eosin (H&E), immunohistochemistry and periodic acid-Schiff (PAS) staining as previously described. 29 The slides were read and interpreted in a blinded fashion, grading the kidneys for glomerular inflammation, proliferation, crescent formation, and necrosis. Interstitial changes and vasculitis were also noted. Scores from 0 to 3 were assigned for each of these features and then added together to yield final renal scores. For example, glomerular inflammation was graded: 0, normal; 1, few inflammatory cells; 2, moderate inflammation; and 3, severe inflammation. Detailed pathological assessment was performed as described previously. 30 The spleens of MRL/lpr mice were collected to calculate the spleen index. Spleen index ¼ spleen weight (g) divided by body weight (g).
Enzyme-linked immunosorbent assay (ELISA)
Concentrations of IL-21 and anti-double-stranded (dsDNA) antibody in serum of MRL/lpr mice were determined by ELISA (ELISA; R&D, Minneapolis, MN, USA). In some experiments, isolated Tfh cells or whole spleen cells (5 Â 10 5 cells) were co-cultured with MSCs at a 5:1 ratio in the presence of 10 ng/ml IL-21 (eBiosience), 20 ng/ml IL-6 (Sigma-Aldrich), 2 mg/ml anti-CD3 antibody (eBiosience), and 2 mg/ml anti-CD28 (eBiosience) antibody for two days and stimulated with 50 ng/ml PMA (SigmaAldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) for the final five hours. IL-21 was then detected in the supernatants by ELISA (eBioscience). þ T cells were co-cultured with MSCs at a different ratio in the presence of anti-CD3, anti-CD28, IL-21, and IL-6 for five days. The proliferation of CFSE-labeled cells was analyzed by flow cytometry.
Flow cytometry
Western blot
þ PD-1 þ Tfh cells were co-cultured with MSCs for two days. Tfh cells were lysed, and proteins were extracted and blotted with antibodies to STAT3, p-STAT3 (Tyr705), and b-actin (Cell Signaling Technology, Beverly, MA, USA). The proteins were detected with SuperSignal West Pico Chemiluminescent Substrate solution (Thermo Scientific, Rockford, IL, USA).
Analyses of cytokine and transcription factor messenger RNA (mRNA) expression
Total RNA was purified with the Trizol reagent (Invitrogen). Then, complementary DNA (cDNA) were synthesized using the Primescript RT Master Mix Perfect Real-time Kit (TaKaRa, Tokyo, Japan), and mRNA expression was examined with the Bio-Rad iCycler 7500 Optical System (BioRad, Richmond, CA, USA) using a SYBR Premix EX Taq Real-time PCR Master Mix (TaKaRa). The 2 -ÁÁCt method was used to normalize transcription to b-actin and to calculate fold-induction relative to controls. The following primer pairs were used: Mus b-actin: forward GAGACCTTCAACACCCCAGC, reverse ATGTCACGCACGATTTCCC; Mus IL-21: forward ACAAGATGTAAAGGGGCACT GT, reverse GAATCACAGGAAGGGCATTTAG; Mus Bcl-6: forward CCTGAGGGAAGGCAAT ATCA, reverse CGGCTGTTCAGGAACTCTTC; and Mus STAT3: forward CCGTCTGGAAAA CTGGATAACT, reverse CCCTTGTAGGACA CTTTCTGCT.
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Statistical analyses
Results were expressed as means AE standard deviation (SD). Statistical significance was determined by analysis of variance (ANOVA) for comparisons of multiple means, Student's t-test, or Mann-Whitney U-test.
Results
Isolation, culture, and identification of BM-MSCs
Bone marrow cells were isolated through density gradient centrifugation from B6 mice, and cultured in DMEM/F12 (1:1) supplemented with 1% penicillin, 1% streptomycin, 15% FBS, and 1% Glutamin-Max. After 48 hours' culture, non-adherent cells were removed, and MSCs were selected by their adherence to the culture dishes. The changes of cell shape and clone formations could be dynamically observed from passage one to passage four (Figure 1(a) ), then MSCs were expanded to passage four and then digested for later usage. Surface markers of cultured MSCs were tested by flow cytometry. To identify the surface markers of MSCs, MSCs were labeled with antibodies like anti-CD45, anti-CD11b, anti-Sca-1, anti-CD44, anti-CD29, anti-CD73, anti-CD105, and anti-CD106. The data showed that cultured BM-MSCs are CD45 (Figure 1(b) ). All together, the cell shapes and surface markers of BM-MSCs were consistent with previous reports, 31 and thus the BMMSCs could then be used for the later investigation.
BM-MSCs could inhibit the development of Tfh cells in vitro
Naı¨ve CD4 þ T cells were isolated from spleens of B6 mice by flow cytometry, and co-cultured with BM-MSCs in the presence of IL-21 and IL-6. 
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BM-MSCs could inhibit CD4
þ T cell proliferation dose-dependently (Figure 2(a) ), and prevent
Tfh cell differentiation from naı¨ve T cells (Figure 2(b) ). In this study, our results indicated that BM-MSCs added to naı¨ve CD4 þ T cell culture at a 1:5 ratio could achieve effectively inhibitory ability on CD4 þ T cell proliferation and CD4 (Figure 2(a) and (b) ). Thus, this 1:5 cell ratio was used in the later research.
To further test whether BM-MSCs inhibit Tfh cells derived from whole splenocytes, BM-MSCs were co-cultured with isolated whole splenocytes from B6 mice for two days. The percentage of CD4 þ CXCR5 þ PD-1 þ Tfh cells were analyzed by flow cytometry; the data showed that BM-MSCs could significantly reduce the percentages of CD4 þ CXCR5 þ PD-1 þ cells (Figure 3(a) and (b) ). IL-21 is a key cytokine produced by Tfh cells, 20 and our data further proved that BM-MSCs could inhibit IL-21 gene expression in splenocytes ( Figure  3(c) ). STAT3 is one of the important signal proteins contributing to Tfh cell differentiation; 32, 33 our data showed that BM-MSCs could reduce the gene expression of STAT3 in splenocytes (Figure 3(d) ).
To further analyze whether BM-MSCs could affect sorted Tfh cells, CD4 þ
CXCR5
þ PD-1 þ Tfh cells were sorted from the spleens of B6 mice by flow cytometry, and co-cultured with BM-MSCs. The data showed that BM-MSCs could effectively inhibit IL-21 gene expression and protein secretion in sorted Tfh cells (Figure 4(a) and (b) ). BCL-6 and STAT3 are two important signal proteins for the differentiation of Tfh cells; 32, 34 our study demonstrated that BM-MSCs could inhibit the gene expression of BCL-6 and STAT3 and the phosphorylation of STAT3 in Tfh cells (Figure 4(c)-(e) ). All these data indicate that BM-MSCs not only prevent Tfh cells development from naı¨ve T cells and splenocytes, but also inhibit IL-21 production from Tfh cells.
BM-MSCs treatment could inhibit Tfh cell expansion in vivo and relieve lupus nephritis
MRL/lpr mice spontaneously develop a severe systemic autoimmune disease similar to human lupus. 35 MRL/lpr mice can develop nephritis with increased 24-hour urine protein and serious renal injuries. 29 In our study, MRL/lpr mice were treated Figure 5(e) ). Lupus is characterized by the overproduction of autoantibodies, and antidsDNA antibody is a key pathogenic autoantibody in the pathogenesis of lupus. BM-MSCs treatment could also effectively inhibit the production of antidsDNA antibody ( Figure 5(f) ).
Tfh cells provide selection signals that are essential for GC formation and autoantibody production. 23, 36 Our in vivo data showed that BM-MSCs treatment could effectively inhibit the expansion of CD4 þ
CXCR5
þ PD-1 þ Tfh cells in spleens of 
Discussion
SLE is a chronic recurrent autoimmune disease that needs long-term persistent treatment. Glucocorticoids and other immunosuppressive agents are widely used in the treatment of lupus. Long-term usage of these drugs often induces diverse side effects, thus it is urgent and necessary to explore new, safe, and effective therapeutic methods for the treatment of SLE. In addition, these new therapeutic methods could be best to treat severe and refractory lupus.
MSCs are key important members of the stem cell family, which are first discovered in bone marrow. 7 MSCs have the potential for multi-directional differentiation into fat, bone, cartilage, muscle, tendon, ligament, nervous system, liver, and myocardium. 7 Compared to other stem cell sources, MSCs appear as a promising source for controlling autoimmunity disease because of their immunosuppressive properties. 8, 18 The usage of MSCs in the treatment of SLE has been proved by several clinical trials 7, 17 that have shown that MSCs are a safe and effective method for the treatment of severe or refractory disease. 37 BM-MSCs infusions could lead to a decrease in SLE disease activity index scores with reduced proteinuria, creatinine and blood urea nitrogen levels. 17 These studies indicate that MSCs are a promising therapeutic method for the treatment of SLE. However, the immunological mechanism of MSCs for the treatment of SLE has not been fully elucidated.
Tfh cells are an important T cell subset contributing to B cell activation and humoral immunity hyperfunction in autoimmune disease. 24, 38 Our previous data confirmed that Tfh cells were expanded in the spleens of MRL/lpr mice and peripheral blood of SLE patients. 26, 27 Moreover, Tfh cells were related to GC formation and renal injuries in MRL/lpr mice, and disease flare of SLE patients. 26, 27 IL-21, a cytokine produced by Tfh cells, 38, 39 was overproduced in sera of MRL/lpr mice and sera of SLE patients, and blocking the combination of IL-21 and IL-21 receptor could reduce autoantibody production in MRL/ lpr mice. 26, 27 These data suggest that Tfh cells are closely related to the autoimmune pathogenesis of lupus. Therefore, Tfh cells and IL-21 could be promising therapeutic targets for the treatment of SLE. Interestingly, in different diseases like urothelial carcinoma and Hodgkin's lymphoma, 40, 41 PD-1 is up-regulated, which prevents the positive immune clearance against tumor cells. Thus, neutralized antibodies to PD-1 have become effective therapeutic targets for the treatment of cancer. 42 These data indicate that PD-1 might play a different role in diverse disease microenvironments.
In our study, bone marrow cells were first isolated from B6 mice, and cultured in vitro. After four passages of culture, bone marrow cells could be successfully induced into MSCs, which were confirmed by cytological morphology and surface markers staining. When MSCs were co-cultured with isolated naı¨ve T cells in Tfh culture media, MSCs could reduce CD4 þ CXCR5 þ PD-1 þ Tfh cell differentiation, and the inhibitory effects were dose dependent. Spleen cells contain a wide variety of lymphocyte subsets, including naı¨ve T cells, matured effector T cells, regulatory T cells, and diverse B cells. In this study, we proved that MSCs could inhibit the differentiation of Tfh cells from whole spleen cells. Furthermore, MSCs could also directly inhibit isolated Tfh cells. All together, these data proved that MSCs not only inhibited de novo Tfh cell generation, but also prevented the proliferation of sorted Tfh cells.
IL-21 not only promotes B cell activation and antibody production, IL-21 is also one of very important cytokines to help Tfh cell differentiation via an autocrine way. 38, 39 In our study, we found that MSCs intervention could depress IL-21 mRNA expression and IL-21 protein secretion. These indicated that MSCs might affect Tfh cell differentiation via blocking up-stream IL-21 stimulation. Bcl-6 is a key transcription factor for the differentiation of Tfh cells; 34 STAT3 is also critical for the differentiation of Tfh cells. 43, 44 Here, we showed that both Bcl-6 gene expression and STAT3 phosphorylation were effectively inhibited by MSCs treatment, while other signal pathways should be further investigated to clarify the complex signal pathway networks during Tfh cell differentiation.
MRL/lpr mice are a spontaneous SLE mouse model with increased urine protein, severe nephritis, and higher mortality. Previous studies have showed that neutralization of IL-21 or IL-21 knockout could decrease Tfh cells in vivo and relieve the disease activity. 45 However, cytokines always hold pleiotropic effects, and our previous study also proved that IL-21 has an immune-regulatory function, 26 and that excessive blocking or neutralization of IL-21 might elicit secondary immune balance disorder and unpredictable side effects. 46 Thus, pleiotropic effects of MSCs might be a reasonable and promising therapeutic method to resolve the complex immune network in vivo of lupus. Here, our study showed that MSCs intravenous injection could effectively elevate the survival rate of MRL/lpr mice, reduce 24-hour urine protein, relieve lupus nephritis and inhibit spleen enlargement. These data proved that MSCs are an effective therapeutic method to treat lupus. The immunologic pathogenesis of lupus is very complicated; our research mainly focused on Tfh cells, and the role of MSCs on Tfh cells in vivo of MRL/lpr mice. Our data showed that MSCs treatment could effectively inhibit CD4 of the targets of MSCs treatment. Of course, we believe that MSCs can also affect other lymphocytes, cytokines or the cytokine network. MSCs not only inhibit effector lymphocytes, but also affect regulatory T or B cells, because several studies have indicated that MSCs could induce regulatory T cells and regulatory B cells in vivo, and promote cytokines with regulatory functions like IL-10 and transforming growth factor beta (TGF-b). 47, 48 Therefore, the complete and detailed therapeutic mechanism of MSCs on the treatment of lupus need to be further investigated.
Conclusions
In summary, our results confirm that MSCs derived from bone marrow cells have immune inhibitory ability, which can inhibit Tfh cell differentiation and IL-21 production. MSCs intravenous treatment could inhibit the differentiation of Tfh cells in vivo, effectively relieve lupus nephritis, and prolong the survival rate of lupus-prone MRL/lpr mice. All together, these data proved that MSCs might be a promising therapeutic method for the treatment of lupus, and MSCs could inhibit Tfh cells both in vitro and in vivo.
